Zhao Yun-Xin, Yao Guang-Li, Sun Jian, Wang Xiao-Lian, Wang Ying, Cai Qiu-Qiong, Kang Hui-Li, Gu Li-Ping, Yu Jia-Shun, Li Wen-Min, Zhang Bei, Wang Jian, Mei Jiang-Jun, Jiang Yi
Department of Ultrasound, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Department of Urology, Shanghai Punan Hospital of Pudong New District, Shanghai, China.
Clin Med Insights Oncol. 2021 Oct 8;15:11795549211049750. doi: 10.1177/11795549211049750. eCollection 2021.
It is valuable to predict the time to the development of castration-resistant prostate cancer (CRPC) in patients with advanced prostate cancer (PCa). This study aimed to build and validate a nomogram incorporating the clinicopathologic characteristics and the parameters of contrast-enhanced ultrasonography (CEUS) to predict the time to CRPC after androgen deprivation therapy (ADT).
Patients with PCa were divided into the training (n = 183) and validation cohorts (n = 37) for nomogram construction and validation. The clinicopathologic characteristics and CEUS parameters were analyzed to determine the independent prognosis factors and serve as the basis of the nomogram to estimate the risk of 1-, 2-, and 3-year progress to CRPC.
T stage, distant metastasis, Gleason score, area under the curve (AUC), prostate-specific antigen (PSA) nadir, and time to PSA nadir were the independent predictors of CRPC (all < 0.05). Three nomograms were built to predict the time to CRPC. Owing to the inclusion of CEUS parameter, the discrimination of the established nomogram (C-index: 0.825 and 0.797 for training and validation datasets) was improved compared with the traditional prediction model (C-index: 0.825 and 0.797), and when it excluded posttreatment PSA, it still obtained an acceptable discrimination (C-index: 0.825 and 0.797).
The established nomogram including regular prognostic indicators and CEUS obtained an improved accuracy for the prediction of the time to CRPC. It was also applicable for early prediction of CRPC when it excluded posttreatment PSA, which might be helpful for individualized diagnosis and treatment.
预测晚期前列腺癌(PCa)患者去势抵抗性前列腺癌(CRPC)发生时间具有重要价值。本研究旨在构建并验证一种列线图,该列线图纳入临床病理特征和超声造影(CEUS)参数,以预测雄激素剥夺治疗(ADT)后CRPC的发生时间。
将PCa患者分为训练队列(n = 183)和验证队列(n = 37),用于列线图的构建和验证。分析临床病理特征和CEUS参数,以确定独立预后因素,并作为列线图的基础来估计1年、2年和3年进展为CRPC的风险。
T分期、远处转移、Gleason评分、曲线下面积(AUC)、前列腺特异性抗原(PSA)最低点及达到PSA最低点的时间是CRPC的独立预测因素(均P < 0.05)。构建了三个列线图来预测CRPC的发生时间。由于纳入了CEUS参数,与传统预测模型相比,所建立列线图(训练集和验证集的C指数分别为0.825和0.797)的辨别力得到提高,并且当排除治疗后PSA时,其仍获得可接受的辨别力(C指数:0.825和0.797)。
所建立的包含常规预后指标和CEUS的列线图在预测CRPC发生时间方面准确性得到提高。当排除治疗后PSA时,其也适用于CRPC的早期预测,这可能有助于个体化诊断和治疗。